Dublin's Actavis has agreed to acquire rival New York drug maker Forest Laboratories Inc. in a cash-and-stock deal that values Forest at about $25 billion. The Wall Street Journal reports that the proposed combination is partly designed to position the resulting company to deal with the changing health-care landscape in the United States.